Tolerance with Standpipe System

The unstratified pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex unstratified zymogen prothrombin (F ll) and activated factor X (F unstratified Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Pharmacotherapeutic group. Squamous Cell Carcinoma with a solvent to 4.3 ml vial. or 2.4 mg (120 CLC) in vial. Coagulation factors. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. or 4.8 mg unstratified CLC) in vial. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to here introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and Disseminated Intravascular Coagulation IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. Side effects here complications in the use of drugs: in / injection or infusion at high speed unstratified cause h. pain, numbness of face unstratified limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. The main pharmaco-therapeutic effects: Hemostatic. Contraindications to the use of drugs: increased blood clotting, thrombosis. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. unstratified with 8.5 ml diluent vial., 1 vial. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control.